首页 | 本学科首页   官方微博 | 高级检索  
     

观察FOLFOX新辅助化疗方案治疗不能切除的进展期胃癌的疗效
引用本文:刘宏斌,盛贤能,韩晓鹏,朱万坤,苏琳,李新源. 观察FOLFOX新辅助化疗方案治疗不能切除的进展期胃癌的疗效[J]. 国际外科学杂志, 2010, 37(3). DOI: 10.3760/cma.j.issn.1673-4203.2010.03.011
作者姓名:刘宏斌  盛贤能  韩晓鹏  朱万坤  苏琳  李新源
作者单位:兰州军区兰州总医院普外科,兰州,730050;兰州军区兰州总医院普外科,兰州,730050;兰州军区兰州总医院普外科,兰州,730050;兰州军区兰州总医院普外科,兰州,730050;兰州军区兰州总医院普外科,兰州,730050;兰州军区兰州总医院普外科,兰州,730050
基金项目:全军医学科学技术研究计划课题 
摘    要:目的 研究奥沙利铂联合氟尿嘧啶和亚叶酸钙(FOLFOX)方案术前进行新辅助化疗对术前评估难以进行根治性手术的进展期胃癌患者的临床疗效及不良反应.方法 入组患者均为兰州军区兰州总医院2008年4月-2009年10月收治的16例晚期胃癌而无法行根治手术.新辅助化疗方案为:奥沙利铂130 mg/m~2第1天;氟尿嘧啶500 mg/m~2、亚叶酸200 mg/m~2第1~5天,每3周为1个周期,共2个周期.观察新辅助化疗后原发病灶的变化情况及用药后的不良反应.结果 新辅助化疗后13例患者获得肿瘤减期,疗程结束后4~6周11例进行根治性手术切除.临床完全缓解(CR)2例,部分缓解(PR)10例,疾病稳定(SD)3例,进展(PD)1例,总有效率为75.0%(12/16).不良反应主要为骨髓抑制、腹泻、恶心呕吐、外周神经感觉异常,经对症治疗后均能缓解.结论 奥沙利铂联合氟尿嘧啶及亚叶酸钙的新辅助化疗方案在不能手术切除的进展期胃癌的治疗中,显著提高手术切除率,耐受性良好,值得推广.

关 键 词:进展期胃癌  新辅助化疗  奥沙利铂

Effects of FOLFOX neoadjuvant chemotherapy protocol on non-resectable advanced gastric Cancer
LIU Hong-bin,SHENG Xian-neng,HAN Xiao-peng,ZHU Wan-kin,SU Lin,LI Xin-yuan. Effects of FOLFOX neoadjuvant chemotherapy protocol on non-resectable advanced gastric Cancer[J]. International Journal of Surgery, 2010, 37(3). DOI: 10.3760/cma.j.issn.1673-4203.2010.03.011
Authors:LIU Hong-bin  SHENG Xian-neng  HAN Xiao-peng  ZHU Wan-kin  SU Lin  LI Xin-yuan
Abstract:Objective To study the clinical efficacy and adverse reactions of the preoperative neo-adjuvant chemotherapy with oxaliplatin plus fluorouracil and calcium folinate (FOLFOX) in the treatment of advanced gastric carcinoma that was difficult to undergo radical operation. Methods We enrolled 16 patients with advanced gastric carcinomas that were unable to undergo radical operation admitted to our hospital from April 2008 to October 2009. The neo-adjuvant chemotherapy regimen was oxaliplatin 130 mg/m~2 for first one, fluorouracil 500 mg/m~2 and calcium folinate 200 mg/m~2 from first day to fifth day,and one treatment course was three weeks and the patients underwent two courses.The changes of the primary lesion and the adverse reactions of the patients were observed. Results Carcinomas of 13 patients were degraded after the treatment, of which, 11 patients underwent radical resections after 4-6 weeks after operation.There were two cases of complete remission (CR) , 10 cases of partial remission (PR), three cases of stable disease(SD) and one case of progress disease(PD) , and the total effective rate was 75.0% (12/16). Adverse reactions included bone marrow suppression, diarrhea, nausea and vomiting and paresthesia, which were relieved after appropriate symptomatic treatment. Conclusions Neoadjuvant chemotherapy with FOLFOX can improve the resection rate of the advanced gastric carcinoma that is unable to undergo radical resection, and the patients' tolerability to this regimen is favorable.Thus, the regimen is worthy of generalizing.
Keywords:Advanced gastric carcinoma  Neoadjuvant chemotherapy  Oxaliplatin
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号